INT132036

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 2005
Last Reported 2010
Negated 2
Speculated 2
Reported most in Body
Documents 126
Total Number 131
Disease Relevance 63.24
Pain Relevance 9.51

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

peptidase activity (DPP4) extracellular region (DPP4) cell adhesion (DPP4)
Golgi apparatus (DPP4) endoplasmic reticulum (DPP4) plasma membrane (DPP4)
Anatomy Link Frequency
plasma 4
body 3
synovial fluid 2
leukocyte 2
nasal 2
DPP4 (Homo sapiens)
Pain Link Frequency Relevance Heat
rheumatoid arthritis 109 99.92 Very High Very High Very High
agonist 644 99.90 Very High Very High Very High
headache 143 99.40 Very High Very High Very High
Inflammation 284 99.10 Very High Very High Very High
substance P 76 98.68 Very High Very High Very High
Bile 4 98.68 Very High Very High Very High
bradykinin 75 97.48 Very High Very High Very High
chemokine 138 97.00 Very High Very High Very High
Dopamine 4 97.00 Very High Very High Very High
Neuropeptide 165 95.72 Very High Very High Very High
Disease Link Frequency Relevance Heat
Renal Cancer 313 100.00 Very High Very High Very High
Disease 478 99.96 Very High Very High Very High
Rheumatoid Arthritis 111 99.92 Very High Very High Very High
Chronic Sinusitis 47 99.90 Very High Very High Very High
Body Weight 348 99.84 Very High Very High Very High
Colon Cancer 218 99.84 Very High Very High Very High
Insulin Resistance 249 99.82 Very High Very High Very High
Weight Loss 286 99.80 Very High Very High Very High
Diabetes Mellitus 4648 99.76 Very High Very High Very High
Pancreatitis 905 99.76 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
With respect to the relationship between DPP IV expression and cancer, the unique example of a clear causal effect is seen in human melanocytes where the loss of DPP IV is invariably associated with malignant transformation [35].
Negative_regulation (loss) of DPP IV in melanocytes associated with malignant neoplastic disease and cancer
1) Confidence 0.59 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2876082 Disease Relevance 0.97 Pain Relevance 0.03
Single doses of sitagliptin markedly and dose-dependently inhibited plasma DPP-IV activity, with approximately 80% or greater inhibition of DPP-IV activity occurring at 50 mg or greater over a 12-hour period and at 100 mg or greater over a 24-hour period.
Negative_regulation (inhibition) of DPP-IV in plasma
2) Confidence 0.58 Published 2005 Journal Clin. Pharmacol. Ther. Section Body Doc Link 16338283 Disease Relevance 0.07 Pain Relevance 0
For dichotomous variables (adverse events), we calculated the odds ratios and 95% CIs for DPP-4 inhibitors versus control.
Negative_regulation (inhibitors) of DPP-4
3) Confidence 0.58 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.16 Pain Relevance 0
Mechanism of action of DPP-4 inhibition
Negative_regulation (inhibition) of DPP-4
4) Confidence 0.58 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.37 Pain Relevance 0
Three DPP-4 inhibitors are currently in late-stage development: vildagliptin, sitagliptin and saxagliptin.
Negative_regulation (inhibitors) of DPP-4
5) Confidence 0.58 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.06 Pain Relevance 0
It could be demonstrated that DPP-4 inhibition increases circulating levels of GLP-1 in experimental animals and that the insulinotropic action of exogenously administered GLP-1 is intensified by DPP-4 inhibition (Holst and Deacon 1998).
Negative_regulation (inhibition) of DPP-4
6) Confidence 0.58 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.14 Pain Relevance 0
Both DPP-4 inhibitors should not be used for patients with moderate or severe kidney problems (EMEA 2007a, 2007b).
Negative_regulation (inhibitors) of DPP-4 in kidney
7) Confidence 0.58 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.45 Pain Relevance 0.03
DPP-4 activity is inhibited by almost 100% at 15 to 30 min after oral ingestion, and more than 80% inhibition lasts for more than 16 hours due to the initial phase of rapid binding followed by a slow phase of very tight binding kinetics (Ahrén et al 2004a).
Negative_regulation (inhibited) of DPP-4
8) Confidence 0.58 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.24 Pain Relevance 0
Headache was reported more often with DPP-4 inhibitors, especially following vildagliptin therapy (data not shown).
Negative_regulation (inhibitors) of DPP-4 associated with headache
9) Confidence 0.58 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.27 Pain Relevance 0.10
Also, serious adverse events were not observed more often following DPP-4 inhibition (odds ratio for vildagliptin 0.86, 95% CI 0.51 to 1.46; odds ratio for sitagliptin 1.07, 95% CI 0.82 to 1.40).
Negative_regulation (inhibition) of DPP-4
10) Confidence 0.58 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2597770 Disease Relevance 0.77 Pain Relevance 0.08
Sitagliptin's inhibition of DPP IV activity may disrupt the normal functions of these polypeptides, particularly in inflamed mucosa [6].
Negative_regulation (inhibition) of DPP IV
11) Confidence 0.55 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2877018 Disease Relevance 0.50 Pain Relevance 0.66
Sitagliptin inhibition of DPP IV may prolong the duration of action of prolyl - peptide substrates that mediate fatigue and weight loss.
Negative_regulation (inhibition) of DPP IV associated with weight loss and fatigue
12) Confidence 0.55 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2877018 Disease Relevance 1.34 Pain Relevance 0.13
Airway inflammation increases mucosal leukocyte density and may decrease glandular DPP IV activity.
Spec (may) Negative_regulation (decrease) of DPP IV in leukocyte associated with inflammation
13) Confidence 0.55 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2877018 Disease Relevance 0.97 Pain Relevance 0.12
However, inhibition of DPP IV maintains the incretins at physiological levels that can increase insulin secretion.
Negative_regulation (inhibition) of DPP IV
14) Confidence 0.55 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2877018 Disease Relevance 0.47 Pain Relevance 0.06
The addition of sitagliptin under these circumstances of reduced DPP IV activity would further inhibit DPP IV's peptidolytic function.
Negative_regulation (reduced) of DPP IV
15) Confidence 0.55 Published 2010 Journal Allergy Asthma Clin Immunol Section Body Doc Link PMC2877018 Disease Relevance 1.07 Pain Relevance 0.24
DPP-4 inhibition may also be used in combination with sulfonylurea and TZDs.
Negative_regulation (inhibition) of DPP-4
16) Confidence 0.54 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2878957 Disease Relevance 0.09 Pain Relevance 0
Saxagliptin is a potent DPP-4 inhibitor, which increases endogenous incretin levels.
Negative_regulation (inhibitor) of DPP-4
17) Confidence 0.54 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2878957 Disease Relevance 0.51 Pain Relevance 0
Sitagliptin was the first DPP-4 inhibitor to be approved in the United States.
Negative_regulation (inhibitor) of DPP-4
18) Confidence 0.54 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2878957 Disease Relevance 0.14 Pain Relevance 0
After stratification by grade, soluble (s)DPP IV activity was twofold significantly decreased in CCRCCs with a low Furhman's grade in comparison to those clear cell carcinomas in a higher grade.
Negative_regulation (decreased) of DPP IV associated with carcinoma
19) Confidence 0.51 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2876082 Disease Relevance 0.39 Pain Relevance 0
Single doses of sitagliptin markedly and dose-dependently inhibited plasma DPP-IV activity, with approximately 80% or greater inhibition of DPP-IV activity occurring at 50 mg or greater over a 12-hour period and at 100 mg or greater over a 24-hour period.
Negative_regulation (inhibited) of plasma DPP-IV in plasma
20) Confidence 0.51 Published 2005 Journal Clin. Pharmacol. Ther. Section Body Doc Link 16338283 Disease Relevance 0.07 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox